Turning Point Brands: FRE Shelf Entry in a ZYN-Dominated Category
Former Category Manager at Family Dollar
inpractise.com/articles/turning-point-brands-fres-shelf-entry-in-a-zyn-dominated-boom
Turning Point Brands: FRE Shelf Entry in a ZYN-Dominated Category(October 16, 2025)
Former Category Manager at Family Dollar
Interview Transcript
This is a snippet of the transcript.Contact Salesto get full access.
Where do you see FRE and Zone's market share in three to five years? I know it's hard to predict.
The one-year outlook for FRE and Zone is for each to reach around 6% market share. That's the target. It's a very competitive market right now. Aside from ZYN, everyone is promoting aggressively. There are offers like "buy two cans, get three free" or "buy one, get one free" with prices as low as $1.99 per can.
This is a snippet of the transcript.Contact Salesto get full access.
Related Content
Swedish Match, Snus, & Smokefree Tobacco Products
Former Managing Director at Swedish Match
Philip Morris, British American Tobacco & the Global Nicotine Market: Reduced-Risk Products' Hurdles to Growth
Former Regional Head, Product Compliance and RRP QA at Philip Morris International
Philip Morris: Reduced Risk Products & Consumer Behavior
Former VP of Marketing at Japan Tobacco
Lifco vs Halma, Danaher, Eurofins, Waters Corp, PM & BAT, Wayfair vs AMZN, Ocado, MongoDB
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.